The FINANCIAL -- Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure.

As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.

Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.

Related Stories

• New Phase 3 data for Tradjenta tablets in black or African American patients with type 2 diabetes
• Innovative public-private collaboration launches to tackle antibiotic research
• Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure